Literature DB >> 14689612

Intratympanic drug therapy with steroids for tinnitus control: a preliminary report.

A Shulman1, B Goldstein.   

Abstract

Intratympanic drug therapy (ITDT) is a surgical technique of instilling medication into the middle ear to perfuse the inner ear in treating hearing loss, tinnitus, vertigo, and ear blockage, alone or in combination, in patients with a predominantly inner-ear site of lesion. This preliminary report of ITDT focuses on attempts at tinnitus control (TC). Between November 1997 and February 1999, 10 patients with severe tinnitus were treated with steroid medication and were last seen in February 2000. TC was established in 7 of these 10 patients (70%). The clinical diagnosis of a predominantly cochlear-type tinnitus was established in each patient by a correlation of the clinical history with a medical-audiological tinnitus patient protocol that included cochleovestibular testing. An additional single patient with sudden hearing loss experienced no hearing improvement on ITDT steroid therapy. Vertigo as an associated complaint was reported by 6 of 10 patients with subjective idiopathic tinnitus. Significant control of the associated vertigo complaint was reported by 5 of 10 patients. Duration of tinnitus relief in 7 of 10 patients was hours in 1 of the 7; days in another of the 7; and 1 year or more in 5 of the 7. One of the seven patients reported TC 3 months after the procedure. Complications included tympanic membrane perforation that persisted for more than 6 months in two patients and an increase in the complaint of ear blockage and tinnitus intensity in one patient. In our preliminary study, ITDT with steroid has resulted in both short- and long-term tinnitus relief in 7 of 10 patients (70%) identified to have a predominantly cochlear-type tinnitus.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 14689612

Source DB:  PubMed          Journal:  Int Tinnitus J        ISSN: 0946-5448


  9 in total

1.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 2.  Local inner-ear drug delivery and pharmacokinetics.

Authors:  Alec N Salt; Stefan K R Plontke
Journal:  Drug Discov Today       Date:  2005-10-01       Impact factor: 7.851

Review 3.  Serum- and glucocorticoid-inducible kinase 1 in the regulation of renal and extrarenal potassium transport.

Authors:  Florian Lang; Volker Vallon
Journal:  Clin Exp Nephrol       Date:  2011-11-01       Impact factor: 2.801

4.  Cochlear microdialysis for quantification of dexamethasone and fluorescein entry into scala tympani during round window administration.

Authors:  Hartmut Hahn; Bernd Kammerer; Andre DiMauro; Alec N Salt; Stefan K Plontke
Journal:  Hear Res       Date:  2006-01-25       Impact factor: 3.208

5.  Intratympanic Injection of Steroid for Treatment of Tinnitus.

Authors:  Chanmiki Sayoo; Satish Kumar
Journal:  Indian J Otolaryngol Head Neck Surg       Date:  2017-09-30

6.  The Efficacy of Intratympanic Steroid Injection in Tinnitus Cases Unresponsive to Medical Treatment.

Authors:  Haydar Murat Yener; Elif Sarı; Mehmet Aslan; Umur Yollu; Emine Deniz Gözen; Ender İnci
Journal:  J Int Adv Otol       Date:  2020-08       Impact factor: 1.017

7.  Effectiveness of Intratympanic Dexamethasone Injection for Tinnitus Treatment: A Systematic Review and Meta-Analysis.

Authors:  Juyong Chung; Doh Young Lee; Jong Seung Kim; Young Ho Kim
Journal:  Clin Exp Otorhinolaryngol       Date:  2022-02-12       Impact factor: 3.372

Review 8.  Intratympanic injection of dexamethasone for treatment of tinnitus in patients with sudden sensorineural hearing loss.

Authors:  Tadao Yoshida; Masaaki Teranishi; Tomoyuki Iwata; Hironao Otake; Tsutomu Nakashima
Journal:  Audiol Res       Date:  2012-01-09

9.  Increased risk of tinnitus in patients with early-onset cataracts: a nationwide population-based case-control study.

Authors:  Yi-Ching Hsieh; Cheng-Hsien Chang; Yi-Yu Tsai; Cheng-Li Lin; Telk-Ying Ng; Chun-Chi Chiang
Journal:  BMC Ophthalmol       Date:  2020-06-16       Impact factor: 2.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.